JesusFranciscoLoveraMD

PubMed

• The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.
  Shannin N Moody, Morganne Manuel, Auriel Willette, Elizabeth Shirtcliff, Brian Copeland
  Journal of the Neurological Sciences. 2024-11-15
• Cytomegalovirus and varicella zoster virus coinfection-associated central hypoventilation syndrome (Ondine's Curse).
  Marine Isakadze, Benjamin Zwain, Alan J Velander, Jesus Lovera
  Eneurologicalsci. 2024-03-01
• 2 citations
  Autoimmune Myelitis and Myocarditis in a Patient With Anti-Aquaporin-4, Antinuclear, and Antiphospholipid Autoantibodies: The Neuromyelitis Optica-Systemic Lupus Eryth...
  Edward C Mader Jr, Olinda Verdecie, Vaniolky Losada, Jesus F Lovera
  Cureus. 2022-11-01

Journal Articles

• A Randomized Trial of Stress Management for the Prevention of New Brain Lesions in MS.  
  Mohr D, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D, Neurology
• American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study.  
  Kim E, Cameron M, Lovera J, Schaben L, Bourdette D and Whitham R, Mult Scler
• Novel method for measurement of fatigue in multiple sclerosis: Real-Time Digital Fatigue Score.  
  Kim E, Lovera J, Schaben L, Melara J, Bourdette D and Whitham R, J Rehabil Res Dev
• Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity.  
  Oken B S, Flegal K, Zajdel D, Kishiyama S S, Lovera J, Bagert B and Bourdette D N, J Rehabil Res Dev
• Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests.  
  Lovera J, Bagert B, Smoot K H, Wild K, Frank R, Bogardus K, Oken B S, Whitham R H and Bourdette D N, J Rehabil Res Dev
• Lipoic acid in multiple sclerosis: a pilot study.  
  Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, Shinto L, Morris C and Bourdette D, Mult Scler
• A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis.  
  Bourdette D N, Edmonds E, Smith C, Bowen J D, Guttmann C R, Nagy Z P, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew R M, Theofan ..., Mult Scler
• Immune-mediated inflammatory demyelinating dysfunction of the nervous system.  
  Lovera J, Hayes A, Brennan K and Adams-Hogan F, South Med J
• Join now to see all

Abstracts/Posters

• Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial.
  Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, ..., Mult Scler
• Clinical trial of a formal group fatigue program in multiple sclerosis.
  Hugos C L, Copperman L F, Fuller B E, Yadav V, Lovera J and Bourdette D N, Mult Scler
• Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclero...
  Vandenbark A A, Culbertson N E, Bartholomew R M, Huan J, Agotsch M, LaTocha D, Yadav V, Mass M, Whitham R, Lovera J, Milano J, Theofan G, Chou Y K, Offner H and Bourde..., Immunology
• Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial.
  Lovera J, Bagert B, Smoot K, Morris C D, Frank R, Bogardus K, Wild K, Oken B, Whitham R and Bourdette D, Mult Scler
• Ginkgo Biloba Improves Cognitive Performance in Multiple Sclerosis Patients with Cognitive Dysfunction: A Pilot Study.
  Bagert B, Lovera J, Oken B, Smoot K, Wild K, Frank R, Bogardus K, Bourdette D, AAN meeting
• Clinical and Neuropsychological Predictors of Neuropsychiatric Symptoms in Subjects with MS and Cognitive Impairment.
  Lovera J, Frohman E, Brown T, Bandari D, Wild K, Rilling L, Yadav V, Whitham R, Stuve O, Bourdette D, AAN meeting
• Randomized Double-blind Placebo-controlled Trial of Memantine 10 mg. Twice a Day for Three Months as a Treatment for Cognitive Impairment in Multiple Sclerosis.
  Lovera J, Frohman E, Brown T, Bandari D, Witham R, Wild K, Bourdette D, AAN meeting
• Join now to see all

Lectures

• Longitudinal Changes on Self-Report of Cognitive Symptoms on the Perceived Deficits Questionnaire in MS: Correlations with Changes in Neuropsychologic Tests and Depres... 
  AAN